ReNeuron partners with Fosun Pharma in China
ReNeuron licenses rights to its CTX and hRPC cell therapy programmes to Fosun Pharma for Chinese market
Proactive Investors ‘ReNeuron Group’s phase IIb stroke trial kicks off with first patient treated’
Proactive investors ‘Breakthrough to open up potential new revenue opportunities for Reneuron Plc’
Positive pre-clinical data in nerve injury
Positive pre-clinical data published using ReNeuron’s CTX cells in artificial nerve tissue generated as part of a grant-funded collaboration
Phase II stroke data presented at AHA conference
Positive long-term data from Phase II stroke disability clinical trial accepted for a late-breaking podium presentation at the American Heart Association International Stroke Conference 2018
Stroke clinical trial regulatory approval in US
FDA approves ReNeuron’s IND application to commence a Phase IIb clinical trial in the US in stroke disability
Proactive Investors: Michael Hunt discusses very encouraging long-term stroke data
To view the full article click here…
Positive stroke clinical data & regulatory update
Long term data from Phase II stroke clinical trial confirm positive results seen after three months.
2017 AGM Trading Update – Shareholder Presentation
September 2017: Please click here to see the slides accompanying the AGM Trading Update presentation.